(Q53237596)

12 May 2018

title

Understanding cancer cell survival is key to patient survival. (English)

1 reference

12 May 2018

author name string

Chris Fegan

series ordinal

1

1 reference

12 May 2018

Chris Pepper

series ordinal

2

1 reference

12 May 2018

publication date

1 February 2015

1 reference

12 May 2018

Lancet Oncology Commission

published in

1 reference

12 May 2018

volume

16

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

122-124

1 reference

12 May 2018

Genomic aberrations and survival in chronic lymphocytic leukemia

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970003-3

7 January 2021

10.1016/S1470-2045(15)70003-3

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018